Release Date: 08-Apr-2022
Global Bispecific Antibody Market Insight 2028 Report Highlights:
Download Report:
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
Download Report:
Cancer has emerged out to be leading cause of death worldwide. For advanced or metastatic cancers, radiotherapy and chemotherapy remain the most effective treatment strategies. However, these therapies are associated with systemic toxicity which limits their use in the market. The surge in prevalence of various cancers associated with high medical need for the development of targeted therapy has propelled the research and development activities in this sector. Bispecific antibodies are relatively new treatment modalities which have entered the market in last few years and demonstrated to overcome the limitations of previously approved cancer therapeutics.
Bispecific antibodies have two binding sites directed at two distinct antigens or two different epitopes on the same antigen. In comparison to monoclonal antibodies, bispecific antibodies have superior clinical efficacy and ability to pass through blood brain barrier. Commercially, two bispecific antibodies including Blincyto and Rybrevant are available in the market which is indicated for the management of cancer. Blincyto (Blinatumomab) is a bispecific CD19 directed CD3 T-cell engager indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Rybrevant developed by Janssen Pharmaceutical is EGF and MET directed bispecific antibody indicated for the management of non-small cell lung cancer.
Since the introduction of Blincyto in 2014, the cancer bispecific antibody market is growing with high rates which can be justified by the ever increasing sales of Blincyto. Further, the introduction of Rybrevant in the market in 2021 is expected to show high adoption rates in the market owing to the single product approval targeting EFGR mutations in lung cancer. In addition, increase in incidences of lung cancer and enhanced efficiency of Rybrevant over other conventional therapies will also boost this segment during the forecast period.
Although only 4 bispecific antibodies have been approved for cancer, the pipeline is highly crowded which points towards positive future of bispecific antibodies in the management of cancer. Mosunetuzumab developed by Biogen is a CD20xCD3 T-cell engaging bispecific antibody in development for the treatment of people with B-cell non-Hodgkin’s lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). It has received breakthrough therapy designation by US FDA and is expected to enter the market in 2022. Apart from this, several other bispecific antibodies are also present in clinical development including FS120, Elranatamab, XmAb819, COM902, and several others. The increased spending by pharmaceutical companies in this segment and the promising pipeline of drugs which are expected to enter the market are the major driving factors to the market.
The cancer bispecific antibody market is highly crowded and consists of several key players including Genmab, Compugen, Janssen, F Star Therapeutics, Gilead Sciences, Sanofi, Celegen Coporation, and others. The presence of large pharmaceutical giants in this region as well as rising partnerships and collaborations between them also favors extensive research activities in this region. For instance in 2021, Loxo Oncology and Merus announced a partnership to develop up to three CD3 engaging T-cell re-directing bispecific antibodies. These rising trends in the global market will lead to new product launches which will drive the growth of market during the forecast period.
The considerable rise in the geriatric population along with shift towards sedentary lifestyle increases the risk of developing the cancer. Moreover, the unavailability of effectively curing drugs and the rate at which conventional therapies are failing possess an unmet need for the development of targeted therapies which will boost the growth of the market. In addition to this, the rising funding by the government as well as private sectors also increases the research and development activities in this area. As per our analysis, the global cancer bispecific antibody market is expected to surpass US$ 20 Billion by 2028.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+9198104